NEW YORK (GenomeWeb News) – Epigenomics today reported flat third quarter revenues year over year as the firm awaits US Food and Drug Administration clearance for its flagship Epi proColon colorectal cancer screening test.

The Berlin-based molecular diagnostics firm reported revenues of €263,000 ($356,000) for the quarter ended Sept. 30, compared to €272,000 for the third quarter of 2012. In a report to investors, the firm said that a decrease in licensing revenue was offset by a more than 23 percent increase in product revenue year over year to €110,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.